Founders Fund VII Management’s AbCellera Biologics ABCL Stock Holding History

Founders Fund VII Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,773,530	Closed	-$11.2M	–	2
2024 Q2	$11.2M	Hold	3,773,530	–	–	86.9%	1
2024 Q1	$17.1M	Hold	3,773,530	–	–	88.05%	1
2023 Q4	$21.5M	Hold	3,773,530	–	–	89.83%	1
2023 Q3	$17.4M	Hold	3,773,530	–	–	89.37%	1
2023 Q2	$24.4M	Hold	3,773,530	–	–	91.35%	1
2023 Q1	$28.5M	Hold	3,773,530	–	–	91.13%	1
2022 Q4	$38.2M	Hold	3,773,530	–	–	94.47%	1
2022 Q3	$37.3M	Hold	3,773,530	–	–	92.58%	1
2022 Q2	$40.2M	Hold	3,773,530	–	–	93.02%	1
2022 Q1	$36.8M	Hold	3,773,530	–	–	91.1%	1
2021 Q4	$54M	Hold	3,773,530	–	–	89.75%	1
2021 Q3	$75.6M	Hold	3,773,530	–	–	86.1%	1
2021 Q2	$83M	Hold	3,773,530	–	–	79.6%	1
2021 Q1	$128M	Hold	3,773,530	–	–	86.19%	1
2020 Q4	$152M	Buy	+3,773,530	New	+$173M	85.11%	1

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Founders Fund VII Management's ABCL Position: Q3 2024 in Review

Founders Fund VII Management sold out of AbCellera Biologics (ABCL) in Q3 2024, closing a stake of 3,773,530 shares — an estimated $11.2M sold.

Founders Fund VII Management first reported a position in ABCL in Q4 2020 and held it in 15 quarters. The position peaked at $152M in Q4 2020. 139 funds tracked by Wall St. Rank hold ABCL as of Q3 2024.

Founders Fund VII Management reported no remaining AbCellera Biologics position as of Q3 2024 after selling out during the quarter.
Founders Fund VII Management sold 3,773,530 AbCellera Biologics shares in Q3 2024, an estimated $11.2M.
Founders Fund VII Management first reported a position in AbCellera Biologics in Q4 2020 and held it in 15 quarters.
Founders Fund VII Management's AbCellera Biologics position peaked at $152M in Q4 2020.
139 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2024.

Based on Founders Fund VII Management's 13F filing for Q3 2024, filed 14 Nov 2024.